Cationic Avidin Nanocarriers for Deep Cartilage Contrast Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug and contrast agent delivery systems fail to effectively penetrate and localize within cartilage, leading to rapid clearance, systemic toxicity, and poor imaging due to the high negative fixed charge density of cartilage, necessitating high doses and multiple injections.
Innovation Solution
A cationic multi-arm Avidin nano-construct is developed, leveraging electrostatic interactions with the cartilage matrix for high penetration and long retention, enabling sustained drug release and enhanced imaging through conjugation with hydrolysable ester linkers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If anionic contrast agents are used for CT imaging of cartilage, then the contrast agents can be administered, but they are repelled by the negatively charged cartilage matrix resulting in poor penetration and retention
Solution Approach 1:
The patent inverts the charge of the contrast agent from anionic to cationic. The cationic contrast agents are conjugated to cationic carriers (such as polyamines or cationic polymers) to overcome the electrostatic repulsion from the negatively charged cartilage matrix. This inversion of charge allows the contrast agents to be attracted to and accumulate in the cartilage tissue, achieving high concentration and long retention time for improved CT imaging.
2Measurement precision
If high doses of contrast agents are administered to achieve sufficient CT attenuation, then imaging quality improves, but local and systemic toxicity increases
Solution Approach 1:
The patent introduces cationic carriers as intermediary substances that facilitate the delivery of contrast agents to cartilage. These carriers (such as polyamines or cationic polymers) act as mediators that interact with the negatively charged cartilage matrix through electrostatic attraction, enabling the contrast agents to accumulate in the tissue at low doses. This intermediary mechanism allows sufficient CT attenuation to be achieved without requiring high doses that would cause toxicity.
Solution Approach 2:
The patent changes the charge parameter of the contrast agent system from negative to positive. By conjugating contrast agents to cationic carriers, the overall charge parameter of the formulation is inverted, which fundamentally alters the interaction with the cartilage matrix. This parameter change enables passive targeting and accumulation in cartilage through electrostatic attraction, achieving high imaging quality at low doses and avoiding toxicity.
3Reliability
If multiple injections of high drug doses are administered to achieve therapeutic effect, then treatment efficacy improves, but systemic toxicity and loss of time increase
Solution Approach 1:
The patent employs sustained release formulations and depot injections that maintain continuous therapeutic action over extended periods. The cationic drug carriers accumulate in cartilage and provide continuous release of therapeutic agents over days or weeks, eliminating the need for multiple separate injections. This continuous action maintains reliable therapeutic efficacy while significantly reducing the time loss associated with repeated injections.
4Quantity of substance
If cationic carriers are used to penetrate cartilage, then penetration and retention improve, but the complexity of the delivery system increases
Solution Approach 1:
The patent modifies the charge parameter of the carrier molecules to be cationic, which fundamentally changes their interaction with the cartilage matrix. This single parameter change (from neutral or anionic to cationic) enables passive electrostatic attraction to the negatively charged GAGs in cartilage, achieving high drug concentration and retention without requiring complex active targeting mechanisms or sophisticated delivery systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nano-construct achieves high intra-cartilage uptake and retention of therapeutic agents, reducing the need for high doses and multiple injections, while providing effective treatment and imaging at low concentrations, minimizing side effects.
Implementation Method 1
A cationic multi-arm Avidin nano-construct is developed, leveraging electrostatic interactions with the cartilage matrix for high penetration and long retention
Implementation Method 2
enabling sustained drug release and enhanced imaging through conjugation with hydrolysable ester linkers
Data Source
AI summary
The present invention provides a platform for the delivery of small molecule drugs or contrast agents to joints and other soft tissues. The platform enables penetration of the drug through the full thickness of cartilage and long intra-cartilage residence time by leveraging electrostatic interactions between the cationic platform and the anionic cartilage matrix. Described herein are compounds and complexes that fit this platform. Also provided are methods of treating a joint disease with the compounds and complexes of the invention, and methods of imaging joints and other soft tissue.